The antibody–drug conjugate target landscape across a broad range of tumour types

Antibody–drug conjugates (ADCs), consisting of an antibody designed against a specific target at the cell membrane linked with a cytotoxic agent, are an emerging class of therapeutics. Because ADC tumour cell targets do not have to be drivers of tumour growth, ADCs are potentially relevant for a wid...

Ausführliche Beschreibung